WO2010085763A1 - Méthodes de détection d'anticorps associés à des maladies auto-immunes utilisant un antigène peptidique hétérogène en trois dimensions - Google Patents

Méthodes de détection d'anticorps associés à des maladies auto-immunes utilisant un antigène peptidique hétérogène en trois dimensions Download PDF

Info

Publication number
WO2010085763A1
WO2010085763A1 PCT/US2010/022009 US2010022009W WO2010085763A1 WO 2010085763 A1 WO2010085763 A1 WO 2010085763A1 US 2010022009 W US2010022009 W US 2010022009W WO 2010085763 A1 WO2010085763 A1 WO 2010085763A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
peptide antigen
antigen
peptide
heterogeneous
Prior art date
Application number
PCT/US2010/022009
Other languages
English (en)
Inventor
Walter L. Binder
Rufus W. Burlingame
Andrea P. Seaman
Original Assignee
Inova Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inova Diagnostics, Inc. filed Critical Inova Diagnostics, Inc.
Publication of WO2010085763A1 publication Critical patent/WO2010085763A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Definitions

  • the present invention is in the field of diagnostic methods for detecting autoimmune disease. More particularly, the present invention relates to systems and methods utilizing three dimensionally heterogeneous peptide antigens with complex structures that bind autoantibodies of at least two different classes, or "isotypes". By diversifying both the antigenic target and the classes of antibodies being detected, sensitivity is enhanced.
  • autoimmune disease arises when the body initiates an immune response against its own tissues and organs. When this occurs, the immune system produces antibodies, also known as autoantibodies, and/or immune cells that target and attack particular cells or tissues of the body. This reaction is called an autoimmune response and is characterized by inflammation and tissue damage.
  • antibodies also known as autoantibodies
  • immune cells that target and attack particular cells or tissues of the body. This reaction is called an autoimmune response and is characterized by inflammation and tissue damage.
  • a variety of immunoglobulin types are often involved in the autoimmune response and their presence in the circulation can be an indication of the progression of the disease.
  • the first antigen encounter activates naive B cells to proliferate and differentiate into IgM antibody- secreting cells.
  • IgM antibody- secreting cells Upon further contact with T- cells, some B-cells start to produce antibodies of other classes such as IgG.
  • autoimmune disorders include rheumatoid arthritis, systemic lupus erythematosus (lupus), and celiac disease. Additional diseases that are believed to be due to autoimmunity include glomerulonephritis, Addison's disease, mixed connective tissue disease, and some cases of infertility. Table 1 lists a number of autoimmune disorders and their conditions, along with known antigenic targets, the sequences of which are reported in the literature. In many cases, the precise peptide sequences of the antigenic epitope associated with the disease is also known.
  • Autoimmune ieactions can be tnggeied in seveial ways They may be triggered when a substance in the body, which is noimally confined to a specific area and hidden fiom the immune system, is released into the bloodstieam oi a normal body substance is altered such as by vii al infection or radiation, oi a foieign substance iesembles a natuial body substance In other cases, the cells that control antibody production, B lymphocytes, malfunction and pioduce abnormal antibodies that attack specific cells of the body In all cases, the underlying problem is similai, the body's immune system becomes misdnected and attacks the veiy oigans it was designed to piotect
  • Heiedity may play a iole m some autoimmune disorders
  • susceptibility to the disordei, iathei than the disoider itself is inheiited
  • a v ⁇ al infection or tissue damage may trigger the development of the disorder.
  • hormonal factors such as estrogen may play a role in the development of autoimmune disease, which may explain why autoimmune disorders are more common among women.
  • Symptoms vary depending on the disorder and the part of the body affected. Some autoimmune disorders affect the body systemically such as the blood vessels, cartilage, or skin while others affect particular organs such as the kidneys, lungs, heart, and brain. The resulting inflammation and tissue damage can cause pain, deformed joints, weakness, jaundice, itching, difficulty breathing, accumulation of fluid (edema), delirium, and death. While the severity of the symptoms depend on the disorder and its progression, autoimmune disease is often debilitating, substantially reducing an individual's quality of life.
  • autoimmune diseases cannot be prevented and to date there are no known cures. While the mechanisms involved in how this disease affects the body are known, its etiology is still unclear, At the simplest level, replacement of the specific secretions of tissues or organs damaged by autoimmune reactions often help.
  • autoimmune disease such as lupus
  • cortisone derivatives that modify the harmful effects of humoral and cellular autoimmune attack on tissues may be administered that allow the body to reestablish immunologic homeostasis.
  • Cytotoxic immunosuppressive drugs may also be utilized to inhibit the activity of immunologically active cells responsible for autoantibody formation or for cytolytic damage to tissues.
  • One disadvantage of these assays is that they detect only a single antigenic sequence of a protein for which a single autoantibody in the biological sample is directed. If the antibody reacting with this one sequence is not present, or an autoimmune response is not strong enough to be detected, these assays could result in a false negative.
  • the detection system is specific for a particular type of antibody class such as IgG and that class of antibody is not produced or is present in such limited quantities that it cannot be easily detected, a false negative would also result.
  • the progression of the disease may be a factor in the ability to detect a certain class of antibody, which demonstrates another disadvantage of some of the above assays.
  • the ability of the autoantibody to bind the antigenic peptide will depend on the three dimensional structure of the antigenic peptide. In many instances, restricting the mobility of the peptide to a less flexible configuration that mimics the binding site of the autoantibody can provide faster and stronger binding. For example, cyclization of the peptides or the formation of multimeric complexes, such as dimers, trimers, tetramers, etc. via intermolecular crosslinking of two or more antigenic peptides can provide the increased rigidity necessary to achieve better results. As discussed elsewhere herein, complex formation results not only in some portion of the peptides being rendered less flexible, but also results in enhancing conformational heterogeneity. In any event, the results obtained are critical for the health care provider to accurately diagnose and initiate treatment for some autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.
  • Assays that utilize a single antigenic peptide with a homogeneous tertiary structure may not be sufficient to identify patients that do not express antibodies to the sequence or express the antibodies at a level not sufficiently above background to have statistical significance. These assays would result in false negatives.
  • those assays that detect the presence of peptide autoantibody complexes using antibody isotype-specific reporter groups would result in false negatives if the patient does not express that particular isotype of immunoglobulin.
  • test devices are needed that can accurately measure antibodies associated with autoimmune disease to facilitate the diagnosis of autoimmune diseases, reduce the number of false negative and false positive results and expedite initiation of treatment.
  • Figure 1 Size exclusion chromatograms of the peptide wherein the cysteine residues were protected with different pairs of protecting groups that were removed preferentially to allow desired sulfhydryl bridging forming a spectacles shaped peptide.
  • Figure 2 Size exclusion chromatograms of (A) the peptide of Figure 1 reduced with DTT showing a primary monomelic peak 3 and multimeric peaks 1 and 2 and (B) the same peptide oxidized showing increased multimeric peaks 1 and 2.
  • Figure 3 Enzyme linked immunosorbent assay showing the activity of the peptide in Figure 1 (not normalized for concentration) demonstrating that all forms of the peptide are active.
  • the present invention is an assay for the detection of antibodies in a patient, and more particularly, to detecting autoantibodies in a patient suspected of having an autoimmune disease.
  • the assay comprises the steps of preparing a three dimensionally heterogeneous peptide antigen, adding a biological sample from the patient to the heterogeneous antigen, and measuring the binding of the heterogeneous antigen to antibodies present in the sample.
  • the heterogeneous peptide antigen comprises at least two different antigenic amino acid sequences from at least one protein associated with an autoimmune response in the patient suspected of having an autoimmune disease.
  • the peptide antigen has an amino acid sequence with at least three cysteine residues that can form two or more disulfide linkages, intramolecularly and intermolecularly, resulting in a heterogeneous population of variably constrained configurations of the antigen (Le. a three dimensionally heterogeneous antigen).
  • the presence of the heterogeneous antigen bound to the autoantibodies in the assay indicates the detection of the autoantibodies.
  • the amino acid sequence of the heterogeneous antigen may also have at least three cysteine residues, or other residues such as lysines, from which at least three covalent linkages from one amino acid to the other may be formed.
  • the heterogeneous antigen When the heterogeneous antigen has four cysteine residues, it can form at least two different intramolecular disulfide bonds resulting in a heterogeneous population of variably constrained configurations of the monomer antigen, and several, even hundreds of, different sets of intermolecular disulfide bonds resulting in the formation of polymers.
  • the heterogeneous antigen contains four or more cysteines, it can form numerous inter-peptide (i.e., between different peptide molecules) antigen disulfide bonds, leading to complex three dimensional structures of dimers, trimers and higher order polymers.
  • the assay may be performed on a variety of biological samples including blood, serum, plasma, saliva, tears, synovial fluid and spinal fluid and may be designed to detect a variety of autoimmune diseases such as rheumatoid arthritis, celiac disease, systemic lupus erythematosus, polymyositis and de ⁇ natomyositis, and the other autoimmune diseases listed in Table 1.
  • the assay may also be performed in a variety of formats including enzyme-linked immunosorbent assay (ELISA), fluorescent immunoassay (FIA), chemical-linked immunosorbent assay (CLIA), radioimmuno assay (RIA) and hnmunoblotting.
  • a heterogeneous antigen having at least two antigenic amino acid sequences (i.e., "epitopes") obtained from or homologous to one or more proteins.
  • epitopopes obtained from or homologous to one or more proteins.
  • these proteins may be filaggrin, fibrinogen, collagen, or vimentin.
  • These one or more antigenic sequences may come from the same protein or different proteins.
  • Representative antigenic sequences for detection of rheumatoid arthritis may be selected from ESTRGRSTR (SEQ ID NO: 1), RKRRGSR (SEQ ID NO: 2), RSRRGR (SEQ ID NO: 3), LERRNNRKG (SEQ ID NO: 4), GVRGPRVEXHQS (SEQ ID NO: 5) and YATRSS (SEQ ID NO: 6). These sequences may be identical to the sequences of the selected protein or they may be modified. In rheumatoid arthritis, certain protein antigenic amino acid sequences comprise one or more arginine residues replaced with citrulline or other amino acids or citrulline analogues.
  • the heterogeneous antigen may comprise antigenic sequences from more than one protein such as filaggrin, fibrinogen, collagen, vimentin and/or PAD-4.
  • the heterogeneous antigen may be further modified by inserting a charged amino acid residue adjacent to each cysteine residue. These charged amino acid residues are selected and placed in the sequence of the heterogeneous antigen to assist in (or to hinder) the formation of cysteine disulfide linkages intramolecularly and intermolecularly. More specifically, oppositely charged amino acid residues are placed adjacent to cysteine residues for which disulfide linkages are desired.
  • identically charged amino acid residues may be positioned adjacent to cysteine residues to reduce their ability to form a disulfide linkage,
  • a proline residue may be inserted into the heterogeneous antigen between two or more of the antigenic amino acid sequences to provide some structural rigidity.
  • the heterogeneous antigen may comprise at least three cysteine residues which may be utilized to influence the three dimensional structure of the heterogeneous antigen itself or for the formation of multimeric complexes containing two or more heterogeneous antigens bound via sulfhydryl bridges.
  • the inclusion of three or more cysteine residues and the choice of neighboring amino acid residues results in a heterogeneous three dimensional structure upon oxidation of the cysteine, such as a mixture of monocyclic, bicyclic, multicyclic, and even more complex "mesh" or "knotted” conformations.
  • the presence of three or more cysteine residues within the heterogeneous peptide antigen results in complex formation via intermolecular bonding between peptides resulting in dimers, trimers, tetramers and other multimers.
  • Such conformational heterogeneity alone improves sensitivity since some autoantibodies may bind to one conformation and other autoantibodies may bind to a different conformation.
  • a heterogeneous antigen comprises one or more of the sequences X 1 EGTRGRTX 2 RKRRGSRX 1 (SEQ ID NO: 7), X 1 EGTRGRTX 2 RSRRGRX 1 (SEQ ID NO: 8), X 1 EGTRGRTRX 2 LERRNNRKGX 1 (SEQ ID NO: 9), X 1 EGTRGRTRX 2 GVRGPRVERHQX 1 (SEQ ID NO: 10), X 1 EGTRGRTR X 2 YATRSSAX 5 (SEQ ID NO: 1 1), X 1 RKRJlGSRX 2 RSRRGRX i (SEQ ID NO: 12), X 1 RKKRGSRX 2 LERRNNRKGX' (SEQ ID NO: 13), X 1 RKRRGSRX 2 G VRGPRVERHQSX 1 (SEQ ID NO: 14), X 1 RKRRGSR X
  • RSRRGRX 2 GVRGPRVERHQSX 1 (SEQ ID NO: 18), X 1 RSRRGRX 2 YATRSSAX 1 (SEQ ID NO: 19), X 1 RSRRGRX 2 ESTRGRTRX 1 (SEQ ID NO: 20), X 1 RSRRGRX 2 KRRGSRX 1 (SEQ ID NO: 21),
  • X 1 LERRNNRKX 2 GVRGPRVERHQSX 1 (SEQ ID NO: 22), X 1 LERRNNRKGX 2 YATR S SAX 1 (SEQ ID NO: 23), X 1 LERRNNRKGX 2 ESTRGRTRX ' (SEQ ID NO: 24), X 1 LERRNNRKGX 2 RKRRGSRX ' (SEQ ID NO: 25), X 1 LERRNNRKGX 2 RSRRGRX ' (SEQ ID NO: 26), X 1 GVRGPRVERHQSX 2 Y ATRSSAX 1 (SEQ ID NO: 27), X 1 GVRGPRVERHQSX 2 ESTRGRTRX 1 (SEQ ID NO: 28),
  • X 1 GVRGPRVERHQSX 2 RKRRGSRX 1 (SEQ ID NO: 29), X 1 GVRGPRVERHQSX 2 RSRRGRX ' (SEQ ID NO: 30) and X 1 GVRGPR VERHQSX 2 LERRNNRHGX 1 (SEQ ID NO: 31) wherein one or more of the arginine residues is replaced with citrulline residues;
  • X 1 is -C, C-, CY-, -YC (depending on its orientation) or nothing;
  • X 2 is -CPC-, -CGGC- or nothing and Y is a charged amino acid residue such as tyrosine.
  • the antigen will include at least three or more cysteine residues, and two or more of the sequences above may be joined together so long as the resulting peptide also has three or more cysteine residues.
  • sequences above are assembled in a C C C, C
  • CPC C or C CPC CPC C configuration , where " ' * is any number of five or more amino acids including an antigenic sequence, C is cysteine and P is proline, such that the formation of conformationally diverse antigenic peptide targets is promoted based on variations in disulfide bridge formation via oxidation.
  • sequences above are assembled in a — C C C-, —
  • '"- can be any amino acid and amino acid “tails" ("--") are allowed at the ends of the peptides.
  • the sequences above are incorporated into a peptide having between 9 and 25 amino acids between the internal -CPC- moiety and external cysteines.
  • the covalent crosslinkages may be fonned by chemical modifcation of amino acid side chains by homobifunetional crosslinkers, heterobifunctional crosslinkers, reaction with EDC (l-Ethyl-3(dimethylaminopropyl)carbodiamide hydrochloride) to form a bond between an amino group and a carboxyl group, or other known crosslinking reagents.
  • an assay for the detection of the increased likelihood of developing rheumatoid arthritis comprising the steps of preparing a three dimensionally heterogeneous peptide antigen, adding a biological sample from a patient to the heterogeneous antigen, and measuring the binding of the heterogeneous antigen to the autoantibodies present in the sample.
  • the heterogeneous peptide antigen comprises at least two antigenic amino acid sequences from at least one of the proteins filaggrin, vimentin, fibrinogen and collagen.
  • the amino acid sequence has at least one citrulline amino acid instead of arginine and at least three cysteine residues that can form two or more disulfide linkages intramolecularly and intermolecuiarly resulting in many different three dimensional configurations of the heterogeneous peptide antigen.
  • the presence of the autoantibodies bound to the heterogeneous antigen indicates the detection of an increased likelihood of the autoimmune disease.
  • one embodiment of the present invention is an immunoassay for detection of antibodies in a subject suspected of having an autoimmune disease comprising the steps of:
  • peptide antigen molecules comprise at least two different antigenic amino acid sequences derived from at least one protein associated with an autoimmune disease, and wherein the peptide antigen molecules further comprise at least three cysteine residues;
  • the immunoassay may be a solid phase assay or a liquid phase assay.
  • Representative immunoassays include a fluorescent immunosorbent assay (FIA), a chemiluminescent immunosorbent assay (CLIA), a radioimmunoassay (RIA), an enzyme multiplied immunoassay techniques (EMIT), a solid phase radioimmunoassay (SPRIA), and an enzyme linked immunosorbent assay (ELISA).
  • FIA fluorescent immunosorbent assay
  • CLIA chemiluminescent immunosorbent assay
  • RIA radioimmunoassay
  • EMIT enzyme multiplied immunoassay techniques
  • SPRIA solid phase radioimmunoassay
  • ELISA enzyme linked immunosorbent assay
  • the two different antigenic amino acid sequences may be incorporated into one peptide antigen molecule, such that all of the individual peptides in the plurality of peptide antigen molecules have the same amino acid sequence.
  • they may be incorporated into two or more separate antigen molecules, such that the plurality of peptide antigen molecules include two or more species of peptides, each with a different amino acid sequence.
  • the peptide antigen molecules have four cysteine residues, which are oxidized to form two or more intermolecular bonds between peptide antigen molecules and two or more intermolecular bonds within the peptide antigen molecules.
  • the oxidizing step may be performed by simply exposing the cysteine residues to air.
  • the biological sample is serum or plasma.
  • the antibody isotopes being detected in the immunoassay are IgG and IgA.
  • the detecting step may be accomplished using a fluorescer, an enzyme, a chemiluminescer, a photos ensitizer or suspendable particles.
  • the subject may be suspected of having systemic lupus erythematosus, celiac disease,
  • the heterogeneous peptide antigen may have a sequence selected from the group consisting of SEQ ID NO. 138, SEQ ID NO. 139, SEQ ID NO. 140, SEQ ID NO. 141, SEQ ID NO.
  • SEQ ID NO. 148 SEQ ID NO. 161, SEQ ID NO. 162, SEQ ID NO. 163, SEQ ID NO. 164,
  • SEQ ID NO. 165 SEQ ID NO. 166, SEQ ID NO. 167, SEQ ID NO. 186, SEQ ID NO. 187, SEQ ID NO.
  • a method of enhancing sensitivity of an immunoassay for detection of antibodies in a subject suspected of having an autoimmune disease by using a three dimensionally heterogeneous peptide antigen matrix as a target of the antibodies, wherein the peptide antigen matrix is prepared using the steps of:
  • peptide antigen molecules comprise at least two different antigenic amino acid sequences derived from at least one protein associated with an autoimmune disease, and wherein the peptide antigen molecules further comprise at least three cysteine residues;
  • antibody refers to immunoglobulin molecule that is capable of binding an epitope or antigenic determinant.
  • antibody includes whole antibodies and antigen- binding fragments thereof, including single-chain antibodies.
  • Such antibodies include human antigen binding antibody and antibody fragments, including, but not limited to, Fab, Fab' and F(ab') 2 , Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a V 1 or V n domain.
  • the antibodies may be from any animal origin such as for example mammals including human, murine, rabbit, goat, guinea pig, camel, horse and the like.
  • antigen' or ''antigenic determinant' * or ''antigenic amino acid sequence refers to a molecule or portion of a molecule capable of being bound by an antibody.
  • An antigen, antigenic determinant or antigenic amino acid sequence may be additionally capable of being recognized by the immune system and/or being capable of inducing a humoral immune response and/or cellular immune response leading to the activation of B- and/or T-lymphocytes.
  • autoantibody refers to an immunoglobulin, antigen specific B cell surface receptor (surface immunoglobulin), directed against self-protein, carbohydrate or nucleic acid.
  • control' or "control sample'” refers to one or more biological samples, such as a serum sample, taken from at least one healthy donor.
  • heterogeneous peptide antigen has a dual meaning with respect to the present invention.
  • this term refers to the fact that two or more noncontiguous different antigenic amino acid sequences from a single protein or from more than one protein are synthesized into a single polypeptide.
  • the antigenic amino acid sequences that comprise the heterogeneous peptide antigen are sometimes between 5 and 50 amino acids in length, or 5 and 30 amino acids in length, and even between 5 and 25 amino acids in length.
  • this term refers to the intramolecular and intermolecular bonding between side chains of one or multiple reactive amino acid residues, such as cysteine, within the antigen amino acid sequence or between one or more antigens which result in a heterogeneous population of structures that are variably constrained configurations (i.e. multiple cyclic or shaped configurations of a single antigen as well as dimer, trimer, tetramer and other multimer configurations between two or more antigens).
  • the antigenic substance used in one embodiment of the diagnostic assays of the present invention has a homogeneous primary structure (i.e., the antigen is a collection of molecules, each of which has the same amino acid sequence), but they are allowed to form complex tertiary structures via covalent bond formation.
  • a homogeneous primary structure i.e., the antigen is a collection of molecules, each of which has the same amino acid sequence
  • intramolecularly refers to the ability of amino acid residues within the sequence of a single peptide molecule to form covalent bonds. Such intramolecular binding may be by sulfhydryl bridging between cysteine residues within the amino acid sequence of the peptide molecule resulting in cyclization of the peptide forming cyclic structures.
  • intermolecular refers to the ability to form covalent bonds between the amino acid residues of two or more peptide molecules. Such intermolecular bonds may be formed by fo ⁇ ning sulfhydryl bridges between cysteine residues via oxidation resulting in two, three, four or more heterogeneous peptide antigens forming dimeric, trimeric, tetrameric or niultimeric complexes respectively. The intermolecular bonds may also be formed by chemical crosslinking between amino groups and carboxyl groups by addition of EDC, or by addition of bifunctional crosslinkers.
  • patient * ' or "subject” refers to a variety of animal species that a sample may be obtained from for the detection of the presence of an autoimmune disease. These include but are not limited to mammals, birds, reptiles and fish. More specifically, the patient or subject is a mammal and most specifically, the mammal is a human. The patient may also be suffering from an infectious disease, cancer, a vaccine response, or some other state wherein measuring the antibody response is useful.
  • biological sample refers to any sample that may be obtained or prepared from a patient that would contain a detectable amount of autoantibodies if the patient were to have an autoimmune disease.
  • biological samples such as serum, plasma, saliva, tears, blood, vaginal secretion, semen or homogenized tissue.
  • a protein responsible for the autoimmune response refers to a protein or proteins, which are recognized by antibodies in a subject.
  • amino acid substitution refers to the replacement or conversion of an amino acid residue in a sequence with another molecule.
  • the molecule may be another natural or non-natural amino acid, an organic molecule or other chemical moiety,
  • one amino acid in a sequence being synthesized may be replaced with another amino acid.
  • replacing leucine with isoleucine which would be a conservative substitution wherein one hydrophobic amino acid is replaced with another hydrophobic amino acid.
  • Another conservative substitution would be replacing lysine with serine.
  • one amino acid residue in a sequence is converted to another amino acid.
  • a glutamine may be converted by deamination to a glutamic acid, or an arginine residue converted by deiminase to a citrulline residue.
  • the present invention is an assay for the detection of antibodies in a patient, and more particularly, to detecting autoantibodies in a patient suspected of having an autoimmune disease.
  • the assay comprises the steps of preparing a three dimensionally heterogeneous peptide antigen, adding a biological sample from the patient to the heterogeneous antigen, and measuring the binding of the heterogeneous antigen to antibodies present in the sample.
  • the heterogeneous peptide antigen comprises at least two different antigenic amino acid sequences from at least one protein associated with an autoimmune response in the patient suspected of having an autoimmune disease.
  • the peptide antigen has an amino acid sequence with at least three cysteine residues that can form two or more disulfide linkages, intramolecularly and intermolecularly, resulting in a heterogeneous population of variably constrained configurations of the antigen (i.e. a three dimensionally heterogeneous antigen).
  • the presence of the heterogeneous antigen bound to the autoantibodies in the assay indicates the detection of the autoantibodies.
  • the human immune system protects the body against infection either by generating antibodies against foreign substances or by producing cytotoxic T cells that have receptors that recognize the surfaces of invading or infected cells.
  • These antibodies abbreviated Ig, are proteins that are found in blood or other bodily fluids of vertebrates. They are typically made of basic structural units — each with two large heavy chains and two small light chains — to form, for example, monomers with one basic unit, dimers with two units or pentamers with five units.
  • the large and diverse population of antibodies is generated by random combinations of a set of gene segments that encode different antigen binding sites (or paratopes), followed by random mutations in this area of the antibody gene, which create further diversity. Selection of antibodies with high affinity for the pathogen driving the immune response results in an increased production of reactive antibodies.
  • Antibody genes also re-organize in a process called class switching that changes the base of the heavy chain to another, creating a different isotype of the antibody that retains the antigen specific variable region. Class switching allows a single antibody reactivity to be used by several different parts of the immune system. Production of antibodies is the main function of the humoral immune system.
  • Each antibody class is structurally adapted for a particular biological activity and functions best at a different site in the body. This is why there are several genes for the constant region of the H chain.
  • IgM is a large protein (macroglobuljn) made up of five identical monomelic subunits held together by a small protein (J chain) and largely confined to the circulation. It is also present in the monomelic form on the surface of most B lymphocytes. The secreted form is predominant in early immune responses to most antigens and provides an effective first-line defense against bacteraemia. Although each subunit has a low affinity for antigen, its pentameric structure gives the whole molecule a relatively high avidity. The affinity is a measure of the strength of binding of a single binding unit to an epitope, whereas the avidity is the strength of binding of the entire antibody molecule with its multiple binding sites to several identical epitopes of an antigen. The multiple binding sites of IgM allow it to attach to several identical epitopes on different particulate antigens simultaneously, leading to agglutination. Blood group antibodies are mainly of this class.
  • IgG is the predominant immunoglobulin in the blood stream and tissue fluids, where it combats microorganisms and their toxins. There are four subclasses of IgG, all monomelic
  • IgG antibodies generally have a higher affinity for antigens than IgM. As well as being able to pass from blood to tissues, IgG is the only class of antibody to cross the placenta and this provides the newborn child with useful protection against infections to which the mother is immune.
  • IgA exists in both monomeric and dimeric forms. It is monomeric in the circulation and there are two subclasses. In its dimeric form it provides the primary defense against "local' * infections owing to its abundance in saliva, tears, bronchial secretions, nasal mucosa, prostatic fluid, vaginal secretions and mucous secretions of the small intestine.
  • IgE is present as a monomer at very low levels in the circulation but provides protection for external body surfaces, especially mucosal surfaces by recruiting antimicrobial cells and agents.
  • Mast cells have high-affinity receptors for the Fc region of IgE.
  • IgE is responsible for the symptoms of atopic allergy.
  • IgD is present predominantly as a monomer, together with IgM, on the surface of most B lymphocytes. Its function is at present unclear but it probably acts as an antigen receptor for the control of lymphocyte activation and suppression. It is thought to be absent from memory cells.
  • each antibody class/subclass through its Fc region carries out a particular function.
  • antibodies of different classes may be expressed at different stages of an infection or disease even thought they have the same biological activity, e.g. IgM and IgG in fixing complement.
  • Autoimmune disease occurs when the immune system malfunctions, interpreting the body's own macromolecules or tissues as foreign and producing autoantibodies or immune cells that target and attack particular macromolecules, cells or tissues of the body.
  • the autoimmune response also produces different classes at different stages of an autoimmune disease.
  • the symptoms affect almost every human organ system, including the nervous, gastrointestinal, endocrine, circulatory systems, as well as connective tissues and eyes. They include more than 80 widely varied chronic illnesses that affect 5-7% of the population, about two thirds of which are women. As a group they are the least understood diseases. It is suspected that these diseases have genetic pre-disposition, but are triggered by an infection.
  • Detecting and identifying autoantibodies in these diseases have yielded valuable information for both diagnosis and treatment of autoimmune diseases.
  • diagnostic strategies is utilizing peptides that comprise specific antigenic sequences to capture the autoantibodies. These sequences are identified from the proteins that elicit the autoimmune responses. For example, antigenic sequences of the protein filaggrin have been identified and used in assays to detect the presence of autoantibodies in the serum of patients suspected of having rheumatoid arthritis.
  • the heterogeneous antigen of the present invention comprises at least two antigenic sequences from proteins recognized by autoantibodies generated in autoimmune disease. This feature is important, because not al! patients suffering from a particular autoimmune disease have circulating antibodies to the same exact antigenic epitope, and in many cases, their autoantibodies are directed towards epitopes on entirely different proteins.
  • heterogeneous peptide antigen may also have the same antigenic sequence repeated two or more times, but it is still considered heterogeneous herein, because the multiple crosslinks may put the two epitopes into many different configurations, even if they have the same primary sequence.
  • proteins will vary depending on the autoimmune disease. For example the proteins filaggrin, vimentin, collagen, fibrinogen and PAD-4 have been identified in rheumatoid arthritis and antigenic sequences of these proteins may be utilized to identify the presence of this disease. Since there are over 80 autoimmune diseases that have been identified, heterogeneous antigens may be prepared for a variety of autoimmune diseases from antigenic sequences of the protein or proteins that elicit autoantibody responses. These sequences vary in length and can be identified utilizing routine techniques known in the art. One such technique digests the protein into fragments and another prepares synthetic overlapping peptides of the protein sequence to determine which of the sequences bind specifically to the autoantibody of interest.
  • the two antigenic sequences in the heterogeneous peptide antigen range in length from about 5 to about 30 amino acids, or more particularly from about 6 to about 25.
  • the heterogeneous antigen comprises at least two antigenic sequences and may range in length from about 9 to about 50 amino acid residues, but may have as many as 120 residues. Its size is based on the number and length of the antigenic sequences as well as the increased immunospecificity which are often afforded by presenting smaller regions.
  • a heterogeneous peptide antigen contains no more than about 100, preferably no more than about 70 and usually no more than about 40 amino acid residues.
  • heterogeneous peptide antigen By incorporating more than two antigenic sequences into the heterogeneous peptide antigen, with at least 14 amino acids, such as between 14 and 18 each, between any given three cysteine residues, formation of a three dimensionally diverse antigen population can be accomplished thus enhancing sensitivity.
  • the antigenic sequences may have the identical sequence of a portion of the protein from which it was obtained, or it may be a modified sequence.
  • modified sequences may be functionally or immunologically equivalent variants that occur as natural biological variations (e.g., allelic variants, orthologs, splice variants or post-translational variants), or they may be novel sequences. They may be prepared using standard modification techniques such as for example site-directed or random mutagenesis or chemical synthesis such as replacing one amino acid with another, which preserves or enhances the immunological character and structure.
  • Post-translational modifications occur during the life of the protein and are considered "permissible substitutions" of amino acids that enhance the binding of the antigenic sequence to the autoantibody.
  • f ⁇ laggrin is post translationally modified by deiminase that converts arginine residues to citrulline and in celiac disease deaminase converts glutaniine to glutamic acid in gliadin.
  • deiminase converts arginine residues to citrulline
  • celiac disease deaminase converts glutaniine to glutamic acid in gliadin.
  • modifications within the scope of the present invention, provide for certain advantages in the use of the heterogeneous peptide antigen specifically in its ability to mimic the antigenic site of the protein and affinity for the autoantibody of interest. Such modifications include variants of the antigenic sequences.
  • variant includes any antigenic sequence having an amino acid sequence in which one or more residues have been inserted, deleted or substituted with another residue.
  • peptides containing at least three cysteine residues which are oxidized to form a heterogeneous peptide antigen exhibit enhanced binding of autoantibodies present in patient's serum or plasma.
  • the cysteine could be a naturally occurring amino acid within the protein sequence from which it was obtained or may be added to the sequence during synthesis. This was an unexpected observation that is not thought to be associated with intramolecular binding alone when only two cysteine residues are present in the peptide sequence. However, it was this observation that led to the addition of three or more cysteine residues being incorporated into the peptide sequence.
  • Addition variants may include N- or C -terminal fusions, as well as intrasequence insertion, of single or multiple amino acids. This may also include the addition of cysteine residues at the terminal ends, or internally to the sequence, of the heterogeneous peptide antigen.
  • the cysteine residues may be present in the antigenic sequences because they are part of the native protein sequence, added at the ends of the antigenic sequences or inserted between the antigenic sequences. These cysteine residues join to form disulfide linkages upon oxidation within the heterogeneous peptide antigen or between two or more heterogeneous peptide antigen molecules.
  • the number of conformations that may be formed by the heterogeneous peptide antigen will depend on the number of cysteine residues within the sequence and its degree of oxidation or crosslinking. Controlled or specific disulfide linkage fo ⁇ nation intramolecularly may be accomplished using protecting groups that may be selectively removed thus allowing only those cysteine residues that are unblocked to form disulfide linkages (B. Hargittai and G. Barany J. Peptide Res. 54:468-479, 1999). It is also hypothesized that preferential disulfide linkages may be formed by inserting charged amino acid residues adjacent to the cysteine residues.
  • oppositely charged amino acids are placed adjacent to the cysteine residues desired to form a linkage.
  • certain cysteine residues are flanked by identically charged amino acids, it is anticipated that disulfide formation will not be favored.
  • dimer, trimer, tetramer and multimer complex formation, or intermolecular sulfhydryl bridge formation between two or more heterogeneous peptide antigens may be controlled by the oxidizing conditions and antigen concentration.
  • the number of conformations may be dependent on other forms of intra- and inter-molecular covalent crosslinking that are formed within a heterogeneous antigen and between heterogeneous antigens.
  • the complex size and shape of the antigen may allow a greater mass to bind to the solid phase than a linear or circular peptide, and may lift the antigenic sites higher above the solid phase than a linear form, thus making them more available to the antibodies. All of these may contribute to the increased immunoreactivity of a heterogeneous antigen over a linear or cyclic peptide.
  • the unmodified antigenic amino acid sequence of a known protein provides optimal binding to antibodies in an immunoassay.
  • variations of the known sequence may create antigens having greater binding affinity than the native antigen.
  • Deletion variants may be intrasequence or may be truncations from the N- or C-termini. For example, it has been observed that in the filaggrin antigenic sequences, certain amino acids positioned within two to three amino acids residues of citrulline when removed do not affect the binding affinity of the antigenic sequence for its autoantibody.
  • amino acid substitutions that differ significantly in their effects on the structure (secondary, tertiary, and/or quaternary), in their charge or hydrophobicity of the antigenic sequence.
  • certain of the amino acid residues provide rigidity to the heterogeneous antigen based on its position within sequence.
  • the amino acid proline acts to restrict the conformation of peptides. It has been hypothesized that there is enhanced autoantibody binding resulting in an increased signal when a proline is inserted between the antigenic sequences of the heterogeneous antigen.
  • heterogeneous peptide sequence should still contain at least two antigenic sequences with at least five amino acids each derived from the protein target or targets of interest.
  • Preferred antigenic amino sequences for the preparation of the heterogeneous antigen for the detection of rheumatoid arthritis are: ESTRGRSTR (SEQ ID NO: 1), RKRRGSR (SEQ ID NO: 2), RSRRGR (SEQ ID NO: 3), LERRNNRKG (SEQ ID NO:4), GVRGPRVEXHQS (SEQ ID NO: 5) and YATRSS (SEQ ID NO: 6) wherein one of more of the arginine residues is replaced with a citmlline residue.
  • a heterogeneous antigenic sequence for the detection of rheumatoid arthritis comprises one or more of these antigenic sequences.
  • heterogeneous antigen comprises one or more of the following combined antigenic amino acid sequences: X S EGTRGRTX 2 RKRRGSRX 1 (SEQ ID NO: 7), X 1 EGTRGRTX 2 RSRRGRX 1 (SEQ ID NO: 8), X 1 EGTRGRTRX 2 LERRNNRKGX ' (SEQ ID NO: 9),
  • X i RKKRGSRX 2 ESTRGRTRX l (SEQ ID NO: 16), X 1 RSRRGRX 2 LERRNNRKGX 1 (SEQ ID NO: 17), X 1 RSRRGRX 2 GVRGPRVERHQSX 1 (SEQ ID NO: 18), X 1 RSRRGRX 2 YATRSSAX 1 (SEQ ID NO: 19), X 1 RSRRGRX 2 ESTRGRTRX ' (SEQ ID NO: 20), X 8 RSRRGRX 2 KRRGSRX 1 (SEQ ID NO: 21), X 1 LERRNNRKX 2 GVRGPRVERHQSX 1 (SEQ ID NO: 22), X 1 LERRNNRKGX 2 Y ATRSSAX 1 (SEQ ID NO: 23), X 1 LERRNNRKGX 2 E STRGRTRX 1 (SEQ ID NO: 24), X I LERRNNRKGX 2 RKRRGSRX 1 (SEQ ID NO: 25),
  • X 1 LERRNNRKGX 2 RS RRGRX 1 (SEQ ID NO: 26), X 1 GVRGPRVERHQSX 2 YATRSSAX 1 (SEQ ID NO: 27), X 1 GVRGPRVERHQSX 2 ESTRGRTRX I (SEQ ID NO: 28), X 1 GVRGPRVERHQSX 2 RKRRGSRX 1 (SEQ ID NO: 29), X 1 GVRGPRVERHQSX 2 RSRRGRX 1 (SEQ ID NO: 30), and X 1 GVRGPRVERHQSX 2 LERRNNRHGX 1 (SEQ ID NO: 31) wherein one or more of the arginine residues is replaced with citrulline residues; X 1 is -C, C-.
  • the antigen will include at least three or more cysteine residues, and two or more of the sequences above may be joined together so long as the resulting peptide also has three or more cysteine residues.
  • sequences above are assembled in a C C C, C
  • sequences above are assembled in a --C C C-, —
  • sequences above are incorporated into a peptide having between 9 and 25 amino acids between the internal -CPC- moiety and external cysteines.
  • the heterogeneous antigen may be prepared using recombinant nucleic acid methodologies well known in the art.
  • a DNA segment coding for a heterogeneous antigen of this invention can be synthesized by chemical techniques, for example the phosphotriester method of Matteucci et al, J. Am. Chem. Soc, 103:3185, (1981).
  • the DNA segment can then be ligated into an expression vector, and a host transformed therewith can be used to produce the polypeptide. See, for example, Current Protocols In Molecular Biology, Ausubel et al, eds., John Wiley & Sons, New York, N.Y.; U.S. Patent 4,237,224, 4,356,270, 4,468,464, 4,683,195 and 4,889,818.
  • the heterogeneous antigen can also be prepared using the solid-phase synthetic technique initially described by Merrifield, in J. Am. Chem. Soc, 85:2149-2154 (1963).
  • Other synthesis techniques may be found, for example, in M. Bodanszky et al, Peptide Synthesis, John Wiley & Sons, 2d Ed., (1976) as well as in other reference works known to those skilled in the art.
  • a summary of synthesis techniques may be found in J. Stuart and J. D. Young, Solid Phase Peptide Synthesis, Pierce Chemical Company, Rockford, 111., 3d Ed., Neurath, H. et al, Eds., p. 104-237, Academic Press, New York, N.Y. (1976).
  • those synthetic methods comprise the sequential addition of one or more amino acid residues or suitably protected amino acid residues to a growing polypeptide chain. Normally,-the amino group of the C-terminal amino acid residue is protected by a suitable, selectively removable protecting group. A different, selectively removable protecting group is utilized for amino acids containing a reactive side group such as lysine or cysteine.
  • the protected or derivatized amino acid is attached to an inert solid support through its unprotected carboxyl group.
  • the protecting group of the amino group is then selectively removed and the next amino acid in the sequence having the complementary (amino or carboxyl) group suitably protected is admixed and reacted under conditions suitable for forming the amide linkage with the residue already attached to the solid support.
  • the protecting group of the amino group is then removed from this newly added amino acid residue, and the next amino acid (suitably protected) is then added, and so forth.
  • any remaining terminal and side group protecting groups are removed sequentially or concurrently, to provide the final heterogeneous antigen.
  • different protecting groups may be used that can be removed independently allowing only the desired cystienes to be reactive for disulfide linkage formation (B. Hargittai and G. Barany J. Peptide Res. 54:468-479, 1999 incorporated herein by reference).
  • Derivatives of the heterogeneous antigen may be by chemical or biological modification, including protein post-translation modification, such as acylation (i.e., acetylation or formylation), biotinylation, carboxylation, deamination, glutathionylation, glycosylat ⁇ on, lipidation (i.e., farnesylation, geranylgeranylation,prenylation, myristoylation, palmitoylation, or stearoylation), methylation, nitrosylation, phosphorylation, sulphation, fucosylation, and ubiquitination.
  • protein post-translation modification such as acylation (i.e., acetylation or formylation), biotinylation, carboxylation, deamination, glutathionylation, glycosylat ⁇ on, lipidation (i.e., farnesylation, geranylgeranylation,prenylation, myristoylation, palmitoylation, or stea
  • derivatives may be prepared through crosslinking with disulfide bond formation as well as other crosslinking reagents such as EDC (1-Ethyl- 3(dimethylaminopropyl)carbodiamide hydrochloride) which forms cross linkages between amino groups and carboxyl groups.
  • EDC 1-Ethyl- 3(dimethylaminopropyl)carbodiamide hydrochloride
  • many different types of homo-bifunctional and hetero-bifunctional crosslinking reagents are commercially available and known to those skilled in the art.
  • oxidation by bubbling oxygen through a solution containing the heterogeneous antigen will result in aggressive sulfhydryl bridge formation between local cysteine residues as compared to keeping the solution in an air-tight container.
  • concentration of the antigen in solution can also tend to regulate the size of complex formation, wherein greater concentration will tend to produce a larger population of multimers having higher molecular weight complexes than lower concentrations, which tend to produce smaller populations for multimers having lower molecular weights.
  • FIA fluorescent immunosorbent assay
  • CLIA chemiluminescent immunosorbent assay
  • RIA radioimmuno assay
  • EMIT enzyme multiplied immunoassay techniques
  • SPRIA solid phase radioimmunoassay
  • immunoblotting gel diffusion precipitation reactions
  • immunodiffusion assays in situ immunoassays (e.g., using colloidal gold, enzyme or radioisotope labels, for example), Western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays, etc.), complement fixation assays, immunofluorescence assays, protein A assays, and Immunoelectrophoresis assays, etc.
  • FIA fluorescent immunosorbent assay
  • CLIA chemiluminescent immunosorbent assay
  • RIA radioimmuno assay
  • EMIT enzyme multiplied immunoassay techniques
  • SPRIA solid phase
  • any assay method that results in a signal imparted by the reaction of autoantibodies with a heterogeneous antigen of this invention is considered.
  • Each of those assay methods can employ detecting techniques in which an indicating means is utilized to signal the immunoreaction, and thereby the binding of an autoantibody to be detected with a heterogeneous antigen of this invention.
  • Such means may be either a mixture of two isotype-specific detecting reagents or a detecting reagent capable of recognizing two or more antibody isotypes.
  • a competitive immunoassay with solid phase separation or an immunometric assay for antibody testing is particularly suitable for use in the present invention. See, The Immunoassay Handbook, chapter 2 and Maggio, Enzyme Immunoassay, CRC Press, Cleveland, Ohio (1981); and in Goldman, Fluorescent Antibody Methods, Academic Press, New York, N.Y. ( 1980).
  • One general assay method dete ⁇ nines the presence, and preferably the amount, of autoantibodies in a biological fluid sample in three steps.
  • the biological fluid sample is admixed with a heterogeneous peptide antigen to form an immunoreaction admixture.
  • the antigen is preferably operatively linked to a solid support such that the immunoreaction admixture has both a liquid phase and a solid phase.
  • the immunoreaction admixture is maintained under biological assay conditions for a time period, typically predetermined, sufficient to form a heterogeneous antigen-autoantibody complex in the solid phase.
  • the reactants are usually separated after the maintenance period, typically by washing and retaining the solid-phase.
  • the presence and preferably the amount of complex formed in the second step and thereby the presence or amount of autoantibodies in the biological fluid sample is then determined.
  • Biological assay conditions are those conditions that are able to sustain the biological activity of the immunochemical reagents of this invention and the autoantibody sought to be assayed. Those conditions include a temperature range of about 4° C to about 45° C, a pH value range of about 5 to about 9 and an ionic strength varying from that of distilled water to that of about one molar sodium chloride. Methods for optimizing such conditions are well known in the art.
  • the labeled specific binding agent is a labeled antiimmunoglobulin antibody.
  • One or a mixture of two or more antiimmunoglobulin isotypes, such as anti-IgA anti-IgM and anti-IgG are labeled and utilized. Similar embodiments include using labeled Protein A, which can bind both IgG and IgA, or labeled Jacalin, a lectinn that can bind IgA, and labeled protein G, a bacterial protein that can bind IgG.
  • the present invention incoiporates the use of multiple isotypes of antiimmunoglobulin antibodies to provide signals where one isotype of immunoglobulin is not produced by the patient or to enhance the signal obtained by the binding of two or more bound immunoglobulin isotypes.
  • the label can be a fluorescent agent chemically bound to the antibodies or antigens to form a fiuorochrome that is a useful immuno fluorescent tracer.
  • Suitable fluorescent labeling agents include for example fluorescein isocyanate (FIC), fluorescein isothiocyanate (FITC), 5-dimethylarnine-l-naphthalenesulfonyl chloride (DANSC), tetramethylrhodamine isothiocyanate (TRlTC), lissamine, rhodamine 8200 sulfonyl chloride (RB 200 SC) and the like.
  • the labeling group is an enzyme, such as horseradish peroxidase (HRP), glucose oxidase, or the like, ⁇ n such cases where the principal indicating group is an enzyme such as HRP or glucose oxidase, additional reagents are required to visualize the fact that a receptor-ligand complex (imtmmoreactanf) has formed.
  • additional reagents for HRP include hydrogen peroxide and an oxidation dye precursor such as 2,2'-azino-di-(3- ethyl-benzthiazoline-G-sulfonic acid) (ABTS) or (3, 3 ⁇ 5, 5' tetramethyl benzidine (TMB).
  • Radioactive elements may also be used as labeling agents.
  • exemplary radio-labeling agents are those that produce gamma ray emissions such as 124 I, 125 I, 128 I, 132 I and 51 Cr. Particularly preferred is " I.
  • Another group of useful labeling agents are those elements such as 1 1 C, 18 F, 15 O and 13 N which themselves emit positrons. The positrons so emitted produce gamma rays upon encounters with electrons present in the animal's body. Also useful is a beta emitter, such ⁇ In or 3 H.
  • antibody molecules produced by a hybridoma can be labeled by metabolic incorporation of radioisotope-containing amino acids provided as a component in the culture medium. See, for example, Galfre et ah, Meth. Enzymol. 73:3-46 (1981).
  • the techniques of protein conjugation or coupling through activated functional groups are particularly applicable. See, for example, Aurameas, et ah, Scand. J. Immunol., Vol. 8 Suppl. 7:7-23 (1978), Rodwell et ah, Biotech., 3:889-894 (1984), and U.S. Patent 4,493,795.
  • the diagnostic assay is an ELISA.
  • a heterogeneous antigen is immobilized on a solid support directly or indirectly.
  • An aliquot of a biological sample, such as serum, from a subject suspected of having an autoimmune disease is added to the solid support and allowed to incubate with the heterogeneous antigen on the solid phase.
  • An enzyme-labeled secondary antibody that recognizes a constant region in the autoantibodies present in the sample which have reacted with the heterogeneous antigen is added.
  • this secondary antibody is an anti-human immunoglobulin.
  • the secondary antibody is specific for IgA, IgG, or IgM heavy chain constant regions may be employed.
  • one, two or more, labeled secondary antibodies are utilized to identify the presence of one, two or more isotypes of the autoantibodies present in the biological sample.
  • a colorimetric reagent is added to the solid support.
  • the reaction of the enzyme label with the reagent produces a detectable visible color that can be quantitated.
  • the presence of this signal indicates the presence of the autoantibodies and therefore the presence of the disease.
  • a more in depth description of the ELISA technique is found in Chapter 22 of the 4th Edition of Basic and Clinical Immunology by D. P. Sites et ah, published by Lange Medical Publications of Los Altos, Calif, in 1982 and in U.S. Patents 3,654,090; 3,850,752 and 4,016,043, which are all incoiporated herein by reference.
  • the heterogeneous antigen is typically affixed to a solid matrix by adsorption from an aqueous medium although other modes of affixation applicable to proteins and peptides well known to those skilled in the art may be used.
  • Useful solid matrices are also well known in the art for preparing a solid support containing a reagent affixed thereto.
  • Such materials are water insoluble and include the cross- linked dextran available under the trademark SEPHADEX from Pharmacia Fine Chemicals (Piscataway, NJ.); agarose; microparticles such as latex particles, glass or silicon chips or polystyrene beads about 1 micron to about 5 millimeters in diameter available from Abbott Laboratories of North Chicago, 111.; polyvinyl chloride, polystyrene, cross-linked polyacryl amide, nitrocellulose- or nylon-based webs such as sheets, strips or paddles; or tubes, plates or the wells of a microtiter plate such as those made from polystyrene or polyvinylchloride.
  • Suitable methods for immobilizing the heterogeneous antigen on solid matrices include ionic, hydrophobic, covalent interactions and the like.
  • the solid matrix can be chosen for its intrinsic ability to attract and immobilize the heterogeneous antigen or it may retain an additional molecule, which has the ability to attract and immobilize the heterogeneous antigen.
  • This additional molecule may be a charged substance that is oppositely charged with respect to the heterogeneous antigen itself or a charged substance conjugated to the heterogeneous antigen.
  • the molecule can be any specific binding member, which is immobilized upon (attached to) the solid matrix and which has the ability to immobilize the heterogeneous antigen through a specific binding reaction.
  • the molecule enables the indirect binding of the heterogeneous antigen to a solid matrix before the performance of the assay or during the performance of the assay.
  • the signal producing system is made up of one or more components, at least one of which is a label, which generate a detectable signal that relates to the amount of bound and/or unbound label.
  • the label is a molecule that produces or which may be induced to produce a signal. Examples of labels include fluorescein, enzymes, chemiluminescers, photosensitizers or suspendable particles.
  • the signal is detected and may be measured by detecting enzyme activity, luminescence or light absorbance. Radiolabels may also be used and levels of radioactivity detected and measured using a scintillation counter.
  • Examples of enzymes which may be used to label the anti-human immunoglobulin include ⁇ -D-galactosidase, horseradish peroxidase, alkaline phosphatase, and glucose-6- phosphate dehydrogenase ("G6PDH").
  • Examples of fluorescein which may be used to label the anti-human immunoglobulin include fluorescein, isothiocyanate, rhodamines, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, fluorescamine, and Alexa Fluor® dyes (that is, sulfonated courmarin, rhodamine, xanthene, and cyanine dyes).
  • Chemiluminescers include e.g., isoluminol.
  • the anti-human immunoglobulin may be enzyme labeled with either horseradish peroxidase or alkaline phosphatase.
  • Enzymes may be covalently linked to anti-human immunoglobulins for use in the methods of the present invention using well known methods. Conjugation methods for preparing these labeled anti-human immunoglobulins, are well known in the art. For example, alkaline phosphatase and horseradish peroxidase may be conjugated to antibodies using glutaraldehyde. Horseradish peroxidase may also be conjugated using the periodate method. Commercial kits for enzyme conjugating antibodies are widely available. Enzyme conjugated anti-human specific antibodies are also available from multiple commercial sources.
  • Biotin labeled antibodies may be used as an alternative to enzyme linked antibodies. In such cases, bound antibody would be detected using commercially available streptavidin- horseradish peroxidase detection systems.
  • Enzyme labeled antibodies produce different signal sources, depending on the substrate.
  • Signal generation involves the addition of substrate to the reaction mixture.
  • Common peroxidase substrates include ABTS (2,2'-azinobis(emylbenzothiazoline-6-sulfonate)), OPD (O- phenylenediamine) and TMB (3,3', 5,5'-tetramethylbenzidine). These substrates require the presence of hydrogen peroxide, p-nitrophenyl phospate is a commonly used alkaline phosphatase substrate.
  • the enzyme gradually converts a proportion of the substrate to its end product.
  • a stopping reagent is added which stops enzyme activity.
  • Signal strength is determined by measuring optical density, usually via spectrophotometer.
  • Alkaline phosphatase labeled antibodies may also be measured by fluorometry.
  • the substrate 4-methylumbelliferyl phosphate (4- UMP) may be used.
  • Alkaline phosphatase dephosphorylated 4-UMP to form A- methylumbelliferone (4-MU) the fluorophore. Incident light is at 365 nm and emitted light is at 448 nm.
  • the amount of color, fluorescence, luminescence, or radioactivity present in the reaction is proportionate to the amount of autoantibodies in a sample which react with the heterogeneous antigen.
  • Quantification of optical density may be performed using spectrophotometric or fluorometric methods, including flow cytometers.
  • Quantification of radiolabel signal may be performed using scintillation counting.
  • the assay is a competitive immunoassay, which employs one or more labeled antibodies that binds to the same antigenic sequences of the heterogeneous antigen as the autoantibodies.
  • these labeled antibodies and the autoantibodies in a sample compete for binding the heterogeneous antigen.
  • a constant amount of a labeled antibody is incubated with different concentrations of a sample from a subject.
  • These labeled antibodies may be monoclonal or polyclonal.
  • the antibody may be labeled with a fluoresces enzyme, chemiluminescer, photosensitizer, suspendable particles, or radioisotope. After incubation, bound labeled antibodies are separated from free antibodies. Depending on the signal producing system used and if necessary, an appropriate substrate with which the labeled antibody reacts is added and allowed to incubate. The signal generated by the sample is then measured. A decrease in optical density or radioactivity from before and after addition of the serum sample or between experimental and control samples, is indicative that autoantibodies in the sample have bound to the heterogeneous antigen.
  • an automated detection assay is utilized.
  • Methods for the automation of immunoassays include those described in U.S. Patents 5,885,530, 4,981,785, 6,159,750, and 5,358,691 , each of which is herein incorporated by reference.
  • the analysis and presentation of results is also automated.
  • software that generates a prognosis based on the presence or absence of a series of proteins corresponding to autoimmune or chronic inflammatory disease markers is utilized.
  • the diagnostic assay of the present invention is used for autoantibody detections, it should be understood that the antibodies can be directed to any antigenic sequences of the heterogeneous antigen. These antigenic sequences are normally derived from proteins recognized as being responsible for or associated with the autoimmune response for which the autoantibodies are being generated. Furthermore, these autoantibodies may be of any variety or isotype as described elsewhere herein.
  • the equipment used to produce the peptide is any standard model peptide synthesizer including the ACT 396, 348, 496, RANIN SYMPHONY or ABI 433 A.
  • HPLC models used for the purification of the synthesized peptide can include the BIOCAD 60, BIOCAD 700E, BECKMAN 24karat, PHARMACIA AktaPurifier 10 or Varian Galaxie.
  • the final amino acid composition of the peptides was confirmed by mass spectrometry.
  • the antigenic sequences of further interest were synthesized as a heterogeneous peptide antigen (shown below) having four cystiene residues, one on the N and C terminal ends of the peptide and two internal to the heterogeneous peptide antigen about centrally located having two antigenic sequences on either side of the central cysteine residues.
  • a heterogeneous peptide antigen shown below
  • spacer amino acids were placed between the two centrally located cysteine residues to reduce any steric hinderence affects that could result in diminished disulfide linkage formation because of their close proximity.
  • the spacer amino acid selected was glycine. Representative samples are shown below.
  • CDTHSKXTLLIKTVETXDGQC (SEQ ID NO: 61 )
  • CTHSTKXGHAKSRPVRDC SEQ ID NO: 64
  • CTHSTKXGHAKSXPVRDC (SEQ ID NO: 65)
  • CTHSTKRGHAKSXPVXDC (SEQ ID NO: 66)
  • CEEEMRELXXQVDQLTNDKC (SEQ ID NO: 77)
  • CDNKQEENKENXKXPSSLEC SEQ ID NO: 78
  • CQECRTRKXXGSRVCQDRDC (SEQ ID NO: 91) [00191 ] CHQCHQESTXGXSRGRCGRSGS (SEQ ID NO: 34)
  • CAHPGSXXGGRKXXGSRVSC (SEQ ID NO: 97)
  • Additional exemplary heterogeneous peptide antigens are as follows, with the exception of SEQ ID NOs: 141 and 144 which had only two cysteines (140 and 143, respectively):
  • CQESTXGXSRKXXGSRCGGCREXNRLNXLLXKLQC (SEQ ID NO: 138) [00241] CQESTXGXSRKXXGSRCGGCRGVXGPRVEXHQSQC (SEQ ID NO: 139) [00242] CESTXGXSRKXXGSRCPCRSXXGRYATXSSAEC (SEQ ID NO: 140)
  • CEGPVVVXPLTVXDIQKC (SEQ ID NO: 150)
  • CTENTXLGDNXKXLSEXLEEKC SEQ ID NO: 1528
  • CEGTXGXTRKXXGSRCPCRSXXGRYATXSSAEC SEQ ID NO: 225
  • heterogeneous peptide antigen was then intramolecularly and intermolcecularly crosslinked following synthesis by dissolving the peptide in buffer above pH 8 and stirring to mix the solution with air. No further purification of the heterogeneous antigen was performed following the crosslinking procedure.
  • Crosslinking of the heterogeneous antigen results in a population of unique conformations including linear, looped (both single and multiple loop conformations) as well as complexes of the monomeric antigen into dimers, trimers, tetramers, and multimers, forming a mesh. It is speculated that this population of configurations yields the heterogeneous antigen in a multitude of three dimensional conformations for binding the autoantibody more quickly and with greater affinity.
  • Example 1 Four heterogeneous peptide antigens were synthesized as provided in Example 1 and run on SDS polyacrylamide gel electrophoresis (PAGE).
  • the first peptide (Antigen 1, also referred to as the unmodified peptide), contained at least four cysteine residues and was subsequently tested in both reduced (Antigen 2), minimal sulfhydryl bridging (Antigen 3), and oxidized (Antigen 4), having increased sylfhydryl bridging, forms.
  • Antigen 2 reduced
  • Antigen 3 minimal sulfhydryl bridging
  • Antigen 4 oxidized
  • C C-C C where C is cysteine and "-"is any number of any amino acid, including at least two of the above mentioned antigenic sequences.
  • Antigen 1 was synthesized by standard peptide chemistry.
  • the fully oxidized monomer of the antigen with 4 cysteine residues has a number of conformations based on the different intramolecular disulfide bridges that can be formed.
  • the oxidized forms are generally more compact or shaped than the linear monomer.
  • This heterogeneous peptide antigen can also form polymers through inte ⁇ nolecular disulfide bridges, which yields dimers, trimers and higher polymers of very complex "mesh" conformation.
  • Cl, C2, C3 and C4 are cysteine residues numbered from left to right, or N-terminus of the antigen to the C-terminus with"-" represents any number of both natural and unnatural amino acids,
  • the second peptide (Antigen 2, called '"linear' " ) was synthesized having the same sequence as the first peptide however; the four cysteine residues within the amino acid sequence had been replaced with serine residues preventing intramolecular and intermolecular sulfhydryl bridging.
  • the third peptide (Antigen 3, called “spectacle”) was prepared having the same sequence as the first peptide but configured into a spectacle conformation. Antigen 3 was forced into a "'spectacle” conformation by selective deprotection of the 4 cysteines. Cysteine residues 1 and 2 were protected by a different group than cysteine residues 3 and 4, and the protecting groups were removed sequentially, constraining the available disulfide bond formation. In the spectacle confirmation sulfhydryl bridging occurs between cysteine residues 1 and 2 and residues 3 and 4. It is the structure C1-C2, C3-C4 above.
  • the oxidized peptide was prepared as follows; a 1 mg/ml solution at basic pH was made and 5OuL was placed on parafilm open to the air on a benchtop for one hour. The solution was recovered and the volume was increased to 50 uL with the same buffered solution. This volume was then added to the gel.
  • the reduced peptide was prepared by adding lOuL of a 100 mM solution of dithiotheitol (DTT) to 5OuL of a 1 mg/mL solution of peptide and incubating the mixture for 1 hour.
  • DTT dithiotheitol
  • a heterogeneous antigen with 4 cysteine residues can form 60 different sets of disulfide bonds in a fully oxidized dimer. This means the dimer can have 60 different structures.
  • the cysteine residues in one heterogeneous peptide can be labeled ACl , AC2, AC3 and AC4.
  • the cysteines in an identical heterogeneous peptide will be identified as BCl, BC2, BC3 and BC4.
  • the letters A and B are used to identify the cysteines in the two identical peptides, not to deniark 2 peptides of different amino acid sequences.
  • the 60 possible sets of disulfide bridges in a completely oxidized dimer of a heterogeneous peptide with 4 cysteines are described below.
  • Antigen 4 The forth peptide (Antigen 4, called "cyclic") with a different amino acid sequence than Antigen 1 and containing just 2 end cysteine residues was also synthesized and analyzed by non-reducing SDS PAGE.
  • An antigen with just 2 cysteine residues is an example of a non- heterogeneous antigen since it has less than 3 cysteine ressidues and can only form linear or cyclic structures. It can be represented as:
  • C is cysteine and "-" is any number of any amino acids, natural or unnatural.
  • the cyclic structures formed upon oxidation include monocyclic monomers, as well as monocyclic dimers, etc., but are not heterogeneous because only cyclic structures are formed with very little conformational heterogeneity.
  • a fully oxidized dimer of an antigen with 2 cysteines can form only 2 sets of disulfide bonds.
  • Peptide A has cysteine residues ACl and AC2, while peptide B has cysteine residues BCl and BC2. Since in this example antigens A and B have exactly the same amino acid sequences, the letters are being used to describe the different possible inter- and intra-molecular disulfide bonds. As with the monomer, only a cyclic structure is possible in a fully oxidized dimer of an antigen with 2 cysteine residues.
  • AC 1 -BC 1 , AC2-BC2 [00380] AC1-BC2, AC2-BC1.
  • peptides move in order of their radius of gyration. Peptides with a larger radius of gyration run slower (higher up on the gel) than peptides with a smaller radius of gyration.
  • the radius of gyration is related to the size and shape of the peptide. Because no reducing agent is present, disulfide bonds are preserved, allowing peptides to retain any shape held in place by disulfide bonds, and to retain any polymers formed by intermolecular disulfide bonds.
  • a linear peptide runs slower on a non-reducing SDS PAGE than the same peptide that has shape caused by intramolecular disulfide bonds because the linear peptide has a larger radius of gyration.
  • Five ug/lane of each of the four peptide solutions was added to SDS PAGE: a peptide with a "linear" conformation (Antigen 2), wherein the cysteine residues were replaced with serine and having a molecular weight of 3,758 g/mol. It ran as a linear peptide since there are no cysteine residues present to create intramolecular or intermolecular bonds.
  • the smear of staining material above the third band is inteipreted to be a mixture of the many possible structures formed by trimers, tetramers and higher order polymers. Distinct bands are not observed because there is such a wide range of structures of each polymer, no individual bands are resolved.
  • Example 2 The four antigens in Example 2 were passed through a molecular sieve column.
  • Antigen 3 the spectacle conformation of the peptide, eluted at about 12.9mL ( Figure 1).
  • Antigen I 5 the unmodified peptide reduced with DTT, eluted at about 11 ,8mL ( Figure 2A), and the oxidized form of the unmodified peptide, Antigen 4, eluted at about 12.8mL ( Figure 2B).
  • the underlying principle of SEC is that particles of different sizes will elute (filter) through a stationary phase at different rates. This results in the separation of a solution of particles based on size. Provided that all the particles are loaded simultaneously, or near simultaneously, particles of the same size should elute together.
  • Each size exclusion column has a range of molecular weights that can be separated. The exclusion limit defines the molecular weight at the upper end of this range and is where molecules are too large to be trapped in the stationary phase.
  • the permeation limit defines the molecular weight at the lower end of the range of separation and is where molecules of a small enough size can penetrate into the pores of the stationary phase completely. This results in larger molecules passing through the column matrix faster and eluting more quickly that those of permeable molecular weight which are caught up in the column matrix and are eluted later in time.
  • Each of the chromatograms show primary elution peaks in the range of 11 ,8mL to 12.8mL. Taken in conjunction with the PAGE results for the oxidized and reduced forms of the unmodified peptide, it is believed that these peaks are complex and consist of a number of intramolecularly bound species having similar three dimensional configurations allowing them to elute at slightly different solvent volumes.
  • the peptide treated with DTT, Antigen 1 is generally linear and elutes at 1 1.8mL ( Figure 2A).
  • Peak 1 We interpret Peak 1 to contain oxidized tetramer and higher intermolecularly crosslinked polymers, which are very complex, eluting at or near the exclusion limit of this column.
  • Peak 2 We interpret Peak 2 to be predominantly comprised of oxidized dimers and trimers of the heterogeneous peptide.
  • the peak at 12.8 mL presumably containing substantially more of these conformers than the peak at 11.9 mL.
  • These conformations include the spectacle conformation, the pretzel conformation and the double looped configuration.
  • the spectacles conformation would result from the sulfhydryl bridging of cysteine residues 1 to 2 and 3 to 4, the pretzel conformation would be between 1 to 3 and 2 to 4 and the double looped conformation would be 1 to 4 and 2 to 3.
  • These conformers are identical in molecular weight and not substantially different enough in three dimensional configurations to be clearly separated into peaks on SEC. Consequently, they appear as a single primary peak.
  • cysteine residues that are closest interact (closest neighbor interactions).
  • the closest neighbor may be a cysteine residue of an adjacent molecule as opposed to a cysteine residue within the amino acid sequence of the peptide itself. Consequently, disulfide bridging is promoted under oxidizing conditions and multimer complex formation results when the effective concentration brings antigens into such proximity that disulfide bond formation occurs between neighboring molecules as opposed to intramolecular! y.
  • the major property of a heterogeneous peptide antigen is the large number of different polymers a single antigen with 3 or more cysteine residues can produce, particularly when compared to an antigenwith 2 cysteine residues that can form only cyclic or linear structures.
  • the elution profile using SEC confirms the results seen on PAGE.
  • Enzyme-linked immunosorbent assays were performed on the unmodified peptide and peptides 1 and 3. Saturating amounts of the heterogeneous peptide antigen is bound to the surface of a microwell plate. Pre-diluted controls and diluted patient samples are added to separate wells, allowing any IgG and/or IgA antibodies present to bind to the immobilized antigen. Unbound sample is washed away and an enzyme labeled anti-human IgG/IgA conjugate is added to each well. A second incubation allows the enzyme labeled anti-human IgG and/or IgA to bind to any patient antibodies that have become attached to the microwells.
  • the remaining enzyme activity is measured by adding a chromogenic substrate and measuring the intensity of the color that develops.
  • the assay can be evaluated spectrophotometrically by measuring and comparing the color intensity that develops in the patient wells with the color in the control wells.
  • Both the peptide containing serine residues, peptide 1 , (linearized) and the spectacle form of the peptide, peptide 3 showed reduced activity for the RA sera tested when compared to the activity of the unmodified peptide.
  • Peptide 1 showed the least activity having positive results for 26 of the 66 rheumatoid arthritis patient serum tested.
  • peptide 3 was positive for 40 of the 66 rheumatoid arthritis patient sera tested wherein all those that were positive for peptide 1 were positive for peptide 3.
  • the unmodified peptide showed the most positive results capturing 80% of the rheumatoid arthritis patient sera, 53 out of the 66 tested.
  • the PAGE indicated that there are a number of possible configurations of the peptide as well as complexes made up of two or more peptide bound via cystine residue bonds present in solution. It is because of this that we believe the unmodified peptide demonstrates increased activity over the two isolate configurations of the peptide, the linear and spectacles forms.
  • the multimeric complexes of the peptide may provide a larger structural profile to present the antigen, increasing the distance of the antigen from the surface, in a configuration or configurations more acceptable to binding antibody.
  • Figure 3 shows the Optical Densities (ODs) from the RA patients run on the three ELISAs. They are sorted from highest to lowest ODs on the oxidized fo ⁇ n of the antigen. Antibodies from the RA patients bound more strongly to Antigen 1 , the oxidized heterogeneous peptide, than to either Antigen 3, the "spectacle” fo ⁇ n, or Antigen 2, the linear form, as measured by the higher ODs on the ELISA using Antigen 1. The average OD of all samples was 1.66 OD for the oxidized peptide, 1.02 OD for the "spectacle” form of the antigen, and 0.58 OD for the linear form. Samples reacted more strongly with the "spectacle” form than the linear form, showing that even some structure increases immuno reactivity.
  • ODs Optical Densities
  • the oxidized heterogeneous peptide also showed higher immunoreactivity than the "spectacle” fo ⁇ n or the linear form as measured by sensitivity of detection of antibodies in patients with RA.
  • a typical cutoff for this type of ELISA 51 of the 66 RA patients tested were positive on the oxidized fo ⁇ n, 36 were positive on the "spectacle” form, and only 24 were positive on the linear form.
  • the "spectacle” form again showed higher immunoreactivity than the linear fo ⁇ n.
  • the oxidized form contains at least some epitopes that are not present on the "spectacle” or linear form because the relative reactivities of the antigens are different for different patient samples.
  • oxidized form is more immunoreactive than the other forms is that there is more mass of antigen bound to the ELISA plate. It is possible that a polymer of many antigens together binds to the plate better than individual antigens.
  • oxidized form may be more immunoreactive than the other forms is that part of the antigen may be raised up above the ELISA plate, thus preventing steric hindrance of the reactive site by the ELISA plate, giving more access of the antigen to the antibodies in solution.
  • oxidized form may be more immunoreactive than the other fo ⁇ ns is that there is greater surface area on the oxidized heterogeneous antigen bound to the plate than when the other forms of the antigen are bound to the plate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne le domaine des méthodes de diagnostic visant à détecter une maladie auto-immune. Plus particulièrement, la présente invention concerne des systèmes et des méthodes utilisant des antigènes peptidiques hétérogènes en trois dimensions dont la structure complexe se lie aux auto-anticorps d'au moins deux classes, ou « isotypes », différents. La diversification de la cible antigène et des classes d'anticorps détectées permet d'augmenter la sensibilité.
PCT/US2010/022009 2009-01-23 2010-01-25 Méthodes de détection d'anticorps associés à des maladies auto-immunes utilisant un antigène peptidique hétérogène en trois dimensions WO2010085763A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20581809P 2009-01-23 2009-01-23
US61/205,818 2009-01-23
US23422709P 2009-08-14 2009-08-14
US61/234,227 2009-08-14

Publications (1)

Publication Number Publication Date
WO2010085763A1 true WO2010085763A1 (fr) 2010-07-29

Family

ID=42356239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/022009 WO2010085763A1 (fr) 2009-01-23 2010-01-25 Méthodes de détection d'anticorps associés à des maladies auto-immunes utilisant un antigène peptidique hétérogène en trois dimensions

Country Status (1)

Country Link
WO (1) WO2010085763A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012138294A1 (fr) * 2011-04-05 2012-10-11 Curara Ab Nouveaux peptides qui se lient à des types de cmh (complexe majeur d'histocompatibilité) de classe ii et leur utilisation en vue de diagnostic et de traitement
US9216399B2 (en) 2012-02-07 2015-12-22 Vibrant Holdings, Llc Substrates, peptide arrays, and methods
EP2968435A4 (fr) * 2013-03-12 2016-10-05 Tel Hashomer Medical Res Infrastructure & Services Ltd Peptides destinés au traitement de maladies autoimmunes
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
CN111655734A (zh) * 2019-04-28 2020-09-11 广州市雷德生物科技有限公司 一种促进蛋白二聚体形成的拉链扣结构及其应用
US10816553B2 (en) 2013-02-15 2020-10-27 Vibrant Holdings, Llc Methods and compositions for amplified electrochemiluminescence detection
WO2020221153A1 (fr) * 2019-04-28 2020-11-05 广州市雷德生物科技有限公司 Structure de fermeture à glissière permettant de favoriser la formation d'un dimère protéique et son utilisation
US11168365B2 (en) 2017-05-26 2021-11-09 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006005A1 (fr) * 1986-03-24 1987-10-08 Ortho Pharmaceutical Corporation Peptides synthetiques utiles pour combattre l'htlv-iii, compositions et utilisations desdits peptides
US20030215788A1 (en) * 1989-06-02 2003-11-20 James Blake Cysteine thiol-protected peptides for use in immunoassays
US6706490B1 (en) * 1997-03-19 2004-03-16 Montech Medical Developments Pty. Ltd. Method for detecting rheumatoid arthritis employing the CB10 peptide of mammalian type II collagen as an antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006005A1 (fr) * 1986-03-24 1987-10-08 Ortho Pharmaceutical Corporation Peptides synthetiques utiles pour combattre l'htlv-iii, compositions et utilisations desdits peptides
US20030215788A1 (en) * 1989-06-02 2003-11-20 James Blake Cysteine thiol-protected peptides for use in immunoassays
US6706490B1 (en) * 1997-03-19 2004-03-16 Montech Medical Developments Pty. Ltd. Method for detecting rheumatoid arthritis employing the CB10 peptide of mammalian type II collagen as an antigen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BILBAO ET AL.: "Immunoglobulin G Autoantibodies against Tissue-Transglutaminase. A Sensitive, Cost-Effective Assay for the Screening of Celiac Disease", AUTOIMMUNITY., vol. 35, no. 4, July 2002 (2002-07-01), pages 255 - 259 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012138294A1 (fr) * 2011-04-05 2012-10-11 Curara Ab Nouveaux peptides qui se lient à des types de cmh (complexe majeur d'histocompatibilité) de classe ii et leur utilisation en vue de diagnostic et de traitement
US9216399B2 (en) 2012-02-07 2015-12-22 Vibrant Holdings, Llc Substrates, peptide arrays, and methods
US11565231B2 (en) 2012-02-07 2023-01-31 Vibrant Holdings, Llc Substrates, peptide arrays, and methods
US10486129B2 (en) 2012-02-07 2019-11-26 Vibrant Holdings, Llc Substrates, peptide arrays, and methods
US11815512B2 (en) 2012-09-28 2023-11-14 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US11674956B2 (en) 2012-09-28 2023-06-13 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10746732B2 (en) 2012-09-28 2020-08-18 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10799845B2 (en) 2012-11-14 2020-10-13 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
US10816553B2 (en) 2013-02-15 2020-10-27 Vibrant Holdings, Llc Methods and compositions for amplified electrochemiluminescence detection
US9975944B2 (en) 2013-03-12 2018-05-22 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic peptides for the treatment of autoimmune diseases
EP2968435A4 (fr) * 2013-03-12 2016-10-05 Tel Hashomer Medical Res Infrastructure & Services Ltd Peptides destinés au traitement de maladies autoimmunes
US11168365B2 (en) 2017-05-26 2021-11-09 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
WO2020221153A1 (fr) * 2019-04-28 2020-11-05 广州市雷德生物科技有限公司 Structure de fermeture à glissière permettant de favoriser la formation d'un dimère protéique et son utilisation
CN111655734A (zh) * 2019-04-28 2020-09-11 广州市雷德生物科技有限公司 一种促进蛋白二聚体形成的拉链扣结构及其应用

Similar Documents

Publication Publication Date Title
WO2010085763A1 (fr) Méthodes de détection d'anticorps associés à des maladies auto-immunes utilisant un antigène peptidique hétérogène en trois dimensions
US9267946B2 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
CA3033035C (fr) Methode de diagnostic de pancreatite aigue (ap) par detection d'isoforme alpha de glycoproteine 2 (gp2a)
US9012405B2 (en) Citrullinated fibrin-filaggrin chimeric polypeptide capable of detecting the antibodies generated in rheumatoid arthritis
US6537760B1 (en) Receptor binding assay for detecting TSH-receptor auto-antibodies
Marczinovits et al. A peptide of human muscarinic acetylcholine receptor 3 is antigenic in primary Sjögren's syndrome
EP2913675B1 (fr) Isoformes GP2 et leur utilisation dans la capture d'auto-anticorps
US20100240076A1 (en) Immunoassay involving mutant antigens to reduce unspecific binding
US5891436A (en) Primary biliary cirrhosis autoantigen and method of use
WO2011026200A2 (fr) Nouveaux procédés permettant de diagnostiquer des maladies auto-immunes
KR20020021813A (ko) 이성질화된/임의로 반전된 에피토프에 대한 특이성자가면역 반응: 자가면역 질환 진단의 응용
AU601963B2 (en) Modified beta-2-microglobulin
US6706490B1 (en) Method for detecting rheumatoid arthritis employing the CB10 peptide of mammalian type II collagen as an antigen
US9067982B2 (en) Compositions and methods for redox modulated proteins
US6342394B1 (en) Diagnosis of autoimmune adrenal disease
US20200209258A1 (en) Gp2 isoforms and their use in autoantibody capture
Caponi et al. Detection of anti-ribosome antibodies: a long story of lights and shadows
WO1989005976A1 (fr) Procede de diagnostic de la cirrhose bilaire primaire et anticorps adaptes pour etre utilises dans ledit procede
JP2727477B2 (ja) ＰＴＨｒＰのサンドイッチ法による免疫学的測定法
WO1996038479A1 (fr) Procede de diagnostic du diabete sucre insulino-dependant et kit de diagnostic
JPH02264863A (ja) ヒトイムノグロブリンＦｃ断片と人以外の哺乳動物抗体とのコンジユゲート
DK161098B (da) Antistoffer mod modificeret beta2-mikroglobulin, fremgangsmaader til detektering af modificeret beta2-mikroglobulin samt farmaceutiske praeparater indeholdende saadanne antistoffer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10733979

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10733979

Country of ref document: EP

Kind code of ref document: A1